COMMUNIQUÉS West-GlobeNewswire

Venus Concept Obtains Exclusive Distribution Rights for the HIRONIC Doublo 2.0 Device in US and Canada
28/07/2026
TORONTO, July 28, 2026 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”), a global medical aesthetic technology leader, today announced it has entered into an exclusive distribution agreement [...]
Palvella Therapeutics to Host Second Quarter 2026 Financial Results and Corporate Update Conference Call on August 4, 2026
28/07/2026
WAYNE, Pa., July 28, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc . (Palvella or the “Company”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies [...]
Kazia Therapeutics Announces the Filing of Provisional Patent for Novel Strategy, Supported by Preclinical Data, to Prevent Metastatic Recurrence in Triple-Negative Breast Cancer
28/07/2026
Clinically relevant perioperative studies demonstrate elimination of residual disease and prevention of metastatic spread, supported by complementary translational patient data SYDNEY, July 28, 2026 (GLOBE NEWSWIRE) -- [...]
Dyne Therapeutics Announces U.S. FDA Clearance of Investigational New Drug (IND) Application for DYNE-302 in Facioscapulohumeral Muscular Dystrophy (FSHD)
28/07/2026
- Company’s third program to enter clinical development leveraging FORCE platform with the goal of delivering functional improvement in rare neuromuscular disease - WALTHAM, Mass., July 28, 2026 (GLOBE NEWSWIRE) -- Dyne [...]
Lifecore Biomedical Signs Three New Customer Agreements
28/07/2026
--Technology Transfer Agreement for Regenerative Medicine Late-Stage Development Program-- --Two Additional Agreements Supporting Early-Stage Programs Including Formulation and Development for a Global Medical [...]
Grace Therapeutics Announces Receipt of Type A Meeting Minutes from U.S. Food and Drug Administration
28/07/2026
FDA Did Not Identify Any Clinical Safety or Efficacy Deficiencies and Did Not Request Additional Clinical Data Company Advancing a Dual-Source Manufacturing Strategy, Adding a U.S.-Based Site, Toward NDA Resubmission [...]
Arvinas to Report Second Quarter 2026 Financial Results on August 4, 2026
28/07/2026
NEW HAVEN, Conn., July 28, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will review [...]
Lungpacer Announces Health Economic Analysis Demonstrating Clinical and Cost Benefits of AeroPace in Mechanically Ventilated Patients
28/07/2026
Analysis projects national average cost savings of ~$24,000 per episode alongside improved ventilator weaning outcomes EXTON, Pa., July 28, 2026 (GLOBE NEWSWIRE) -- Lungpacer Medical today announced results from a new [...]
Cullinan Therapeutics Announces Positive End-of-Phase 1 Meeting with FDA for CLN-049 and Advances Program to a Potentially Registrational Phase 2 Study in AML
28/07/2026
CAMBRIDGE, Mass., July 28, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, disease-modifying T [...]
Atea Pharmaceuticals Meets Both Its Primary and Secondary Endpoints in the Phase 3 C-BEYOND North America Trial Evaluating Bemnifosbuvir/Ruzasvir for Hepatitis C Virus
28/07/2026
Bemnifosbuvir/Ruzasvir (BEM/RZR) Achieved its Primary Endpoint of Statistical Non-inferiority Compared to Sofosbuvir/Velpatasvir (SOF/VEL; Epclusa ® ), a Standard-of-Care, in First-Ever Successful Head-to-Head Trial in [...]
Syndax to Announce Second Quarter 2026 Financial Results and Host Conference Call and Webcast on August 4, 2026
28/07/2026
NEW YORK, July 28, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that it will report its second [...]
Repligen Reports Second Quarter 2026 Financial Results and Updates Full Year 2026 Financial Guidance
28/07/2026
Second quarter revenue of $204 million, a year-over-year increase of 12% as reported and 13% organic GAAP operating income increased 1% year-over-year while adjusted operating income increased 55% Raising both FY26 [...]
Antag Therapeutics Announces Dosing of First Patient in Phase 2a Trial of First-in-Class GIPR Antagonist AT7687
28/07/2026
The Phase 2a study will evaluate AT7687 as a differentiated combination treatment approach for people living with obesity and type 2 diabetes A 13-week study of 150 randomized participants receiving either once-weekly [...]
Transactions in connection with share buy-back program
28/07/2026
Company announcement no. 27 - 26 28 July 2026 Transactions in connection with share buy-back program On 4 March 2026 NTG Nordic Transport Group (“NTG”) announced a share buy-back program, as described in company [...]
Promatix Biosciences Awarded Innovate UK Biomedical Catalyst Grant to Advance First-in-Class EGFR × EphA2 Cis-Bispecific ADC
28/07/2026
Promatix Biosciences Awarded Innovate UK Biomedical Catalyst Grant to Advance First-in-Class EGFR × EphA2 Cis-Bispecific ADC Non-dilutive Biomedical Catalyst funding from Innovate UK will support the advancement of [...]
Xeltis raises an additional €20.5m of funding to advance aXess™ toward FDA approval and US commercial launch
28/07/2026
New investor Horizon 3 Healthcare led the round, which was supported by the European Innovation Council, Invest-NL, VI Partners, EQT Life Sciences, DaVita and other current shareholders Builds on the €50m secured in [...]
Aqua free Supports Drinking Water Project in Tanzania
28/07/2026
Hamburg, 28.07.2026 - Access to safe water is still not given in many parts of the world. In Lower Moshi, a region south of Mount Kilimanjaro in Tanzania, communities and schools struggle with contaminated drinking [...]
Aqua free soutient un projet d’accès à l’eau potable en Tanzanie
28/07/2026
Hamburg, 28.07.2026 - Dans de nombreuses régions du monde, l’accès à une eau potable sûre est encore loin d’être garanti. Dans le Lower Moshi, une région située au sud du Kilimandjaro, en Tanzanie, les communautés [...]
Tensive reports pivotal 12-month clinical trial data confirming REGENERA™ delivers natural breast reconstruction after lumpectomy
28/07/2026
Good-to-excellent cosmetic outcomes 30 of 94 patients enrolled have now reached 24 months of follow-up High surgeon satisfaction sustained through study to date Improvements in patient-reported breast satisfaction and [...]

Pages